Abstract
Hypoxia is a characteristic feature of many solid tumors which has been described in a wide range of tumor types. Its presence impairs the effectiveness of common anti-cancer therapies and accordingly, tumor hypoxia has been associated with an aggressive tumor phenotype, poor response to radio- and chemotherapy, and worse prognosis. In order to predict outcome and identify patients with a worse prognosis and/or patients that would benefit from appropriate treatments, in vivo measurement of tumor hypoxia is required. Given the difficulties associated with invasive methods, a non-invasive method is of major clinical interest. Although several candidate molecules have been labeled with PET and SPECT labels, none of them is used in daily clinical routine due to a number of difficulties that complicate their use. This review aims to give an overview of the most important hypoxia tracers, their prognostic significance and how these tracers can play a role in tomorrows personalized medicine.
Keywords: Hypoxia, PET, SPECT, nitroimidazole.
Current Pharmaceutical Design
Title:Radiolabelled Probes Targeting Tumor Hypoxia for Personalized Medicine
Volume: 20 Issue: 14
Author(s): Gilles Mees, Mike Sathekge, Alex Maes and Christophe Van de Wiele
Affiliation:
Keywords: Hypoxia, PET, SPECT, nitroimidazole.
Abstract: Hypoxia is a characteristic feature of many solid tumors which has been described in a wide range of tumor types. Its presence impairs the effectiveness of common anti-cancer therapies and accordingly, tumor hypoxia has been associated with an aggressive tumor phenotype, poor response to radio- and chemotherapy, and worse prognosis. In order to predict outcome and identify patients with a worse prognosis and/or patients that would benefit from appropriate treatments, in vivo measurement of tumor hypoxia is required. Given the difficulties associated with invasive methods, a non-invasive method is of major clinical interest. Although several candidate molecules have been labeled with PET and SPECT labels, none of them is used in daily clinical routine due to a number of difficulties that complicate their use. This review aims to give an overview of the most important hypoxia tracers, their prognostic significance and how these tracers can play a role in tomorrows personalized medicine.
Export Options
About this article
Cite this article as:
Mees Gilles, Sathekge Mike, Maes Alex and Wiele Van de Christophe, Radiolabelled Probes Targeting Tumor Hypoxia for Personalized Medicine, Current Pharmaceutical Design 2014; 20 (14) . https://dx.doi.org/10.2174/13816128113196660662
DOI https://dx.doi.org/10.2174/13816128113196660662 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Prevention of Macrovascular Disease in Type 2 Diabetic Patients: Blockade of the Renin-Angiotensin-Aldosterone System
Current Diabetes Reviews Novel Treatments in Diabetic Nephropathy
Current Hypertension Reviews A Systematic Review of a Naturally Occurring Iridoid: Catalpol
Current Bioactive Compounds Anti-Inflammatory Agents in Ageing and Age-Associated Diseases
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Resveratrol Improves Cardiovascular Function in DOCA-Salt Hypertensive Rats
Current Pharmaceutical Biotechnology Metabolic Profiling in Disease Diagnosis, Toxicology and Personalized Healthcare
Current Pharmaceutical Biotechnology ESVS Guidelines: Section B - Diagnosis and Investigation of Patients with Carotid Stenosis
Current Vascular Pharmacology Acute Coronary Syndromes in Patients with Atrial Fibrillation and Heart Failure. Could Novel Oral Anticoagulants be the Solution of the Optimal Antithrombotic Therapy Puzzle?
Cardiovascular & Hematological Agents in Medicinal Chemistry Role of Nuclear Steroid Receptors in Apoptosis
Current Medicinal Chemistry Therapeutic Use of Antioxidants in Sepsis
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Impact of Immunosuppressive Drugs on the Development of Cardiac Allograft Vasculopathy
Current Vascular Pharmacology Relaxin in Vascular Physiology and Pathophysiology: Possible Implications in Ischemic Brain Disease
Current Neurovascular Research Blockade of Renin Angiotensin System in Heart Failure Post-Myocardial Infarction: What is the Best Therapy?
Recent Patents on Cardiovascular Drug Discovery Retraction Note: Phytochemicals from Plants to Combat Cardiovascular Disease
Current Medicinal Chemistry Hydrogen Sulfide in Diabetic Complications: Focus on Molecular Mechanisms
Endocrine, Metabolic & Immune Disorders - Drug Targets Diabetic Cardiomyopathy: Clinical and Metabolic Approach
Current Vascular Pharmacology Virus Vasculopathy and Stroke: An Under-Recognized Cause and Treatment Target
Infectious Disorders - Drug Targets Sex-Genetic Interaction in the Risk for Cerebrovascular Disease
Current Medicinal Chemistry The Patented Uses of D-Ribose in Cardiovascular Diseases
Recent Patents on Cardiovascular Drug Discovery Effects of Sodium-Glucose Cotransporter-2 Inhibitors on Cardiac Structural and Electrical Remodeling: From Myocardial Cytology to Cardiodiabetology
Current Vascular Pharmacology